TABLE 3.
Development of SARS-CoV-2 Immunoglobulin based treatments option.
| Leading candidate | Description | Trial sponsor(s) | Development of stage |
| Convalescent plasma | Passively transfer antibodies (Immunoglobulin) | USA FDA -Sponsored | Phase-III |
| Expanded access program coordinated by Mayo Clinic | |||
| STI-5656 (Abivertinib) | Tyrosine kinase inhibitor | Sorrento Therapeutics | Phase-III |
| PRO 140 (Leronlimab) | Monoclonal antibody targeted against CCR5 receptor | CytoDyn Inc., United States | Phase-III |
| PTC299 | Dihydroorotate dehydrogenase inhibitors | PTC therapeutics, Inc., South Plainfield, NJ, United States | Phase-III |
| CD24Fc | Immunomodulator (New drug) | Oncolmmune, Inc., United States | Phase-III |
| Lenzilumab | Chronic Myelomonocytic leukemia | Targets Colony Stimulating factors (CSF-2); Multiple countries | Phase-III |
| Tocilizumab | Immunosuppression | Roche holding AG, Basel, Switzerland | Phase-III |
| Sarilumab | Rheumatoid arthritis | Regeneron-Sanofi, United States | Phase-III |
| Ravulizumab | Compliment inhibitors | Alexion pharmaceuticals Inc | Phase-III |
| Losmapimod | MAPK as potent suppressors of DUX4 expression | Fulcrum Therapeutics, United States | Phase-III |
| Pepcid | H2 blocker | Yamanouchi Pharmaceutical Co., Merck, Japan | Phase-III |
| Mitigare (Colcrys) | Anti-inflammatory agent | Bill & Melinda Gates Foundation, United States | Phase-III |